Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]

To join this study, people generally need to be 18 years or older and have a specific type of lung cancer called non-small cell lung cancer (NSCLC) that's been diagnosed at an earlier stage (IB to IIIA). You must have had your cancer completely removed by surgery between 4 and 12 weeks before joining, and you should have recovered well from the operation.

It's also important that your general health is good, meaning your body is working well enough to be part of the study, and that you are otherwise fit and active with an ECOG performance status of 0 or 1. If you've had a detailed look at the lymph nodes in your chest during or after surgery, that's also a key part of the requirements.

You also must be suitable to receive a type of chemotherapy that contains cisplatin, and importantly, women who could become pregnant need to make sure they are using effective birth control.

If you join this study, you'll first complete up to four cycles of standard chemotherapy that includes cisplatin. After that, you'll be randomly assigned to one of two groups. One group will receive the study drug, Atezolizumab, given as an infusion, every three weeks for a total of 16 cycles (about one year). The other group will receive "best supportive care," which means you'll get regular medical care to manage your health and symptoms, but without the study drug.

Throughout the study, you'll have regular visits to the clinic for check-ups, blood tests, and scans to monitor your health and how you're responding to treatment. The total duration of your participation in the treatment phase of the study will vary depending on your assigned group, but follow-up to track your health outcomes will continue for a longer period. More details about the exact number of visits, tests, and follow-up schedule would be provided by the study team.